PT - JOURNAL ARTICLE AU - JW Cherrie AU - MPC Cherrie AU - A Davis AU - D Holmes AU - S Semple AU - S Steinle AU - E MacDonald AU - G Moore AU - M Loh TI - Contamination of air and surfaces in workplaces with SARS-CoV-2 virus: a systematic review AID - 10.1101/2021.01.25.21250233 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.25.21250233 4099 - http://medrxiv.org/content/early/2021/01/26/2021.01.25.21250233.short 4100 - http://medrxiv.org/content/early/2021/01/26/2021.01.25.21250233.full AB - Objectives This systematic review aimed to evaluate the evidence for air and surface contamination of workplace environments with SARS-CoV-2 RNA and the quality of the methods used to identify actions necessary to improve the quality of the data.Methods We searched Web of Science and Google Scholar until 24th December 2020 for relevant articles and extracted data on methodology and results.Results The vast majority of data come from healthcare settings, with typically around 6 % of samples having detectable concentrations of SARS-CoV-2 RNA and almost none of the samples collected had viable virus. There were a wide variety of methods used to measure airborne virus, although surface sampling was generally undertaken using nylon flocked swabs. Overall, the quality of the measurements was poor. Only a small number of studies reported the airborne concentration of SARS-CoV-2 virus RNA, mostly just reporting the detectable concentration values without reference to the detection limit. Imputing the geometric mean air concentration assuming the limit of detection was the lowest reported value, suggests typical concentrations in health care settings may be around 0.01 SARS-CoV-2 virus RNA copies/m3. Data on surface virus loading per unit area were mostly unavailable.Conclusion The reliability of the reported data is uncertain. The methods used for measuring SARS-CoV-2 and other respiratory viruses in work environments should be standardised to facilitate more consistent interpretation of contamination and to help reliably estimate worker exposure.Key messagesWhat is already known about this subject?Low level contamination of air and surfaces in hospitals with SARS-CoV-2 RNA have been reported during the Covid-19 pandemic.Limited data have published from non-healthcare settings.What are the new findings?Typically, around 6% of air and surface samples in hospitals were positive for SARS-COV-2 RNA, although there is very limited data for non-healthcare settings.The quality of the available measurement studies is generally poor, with little consistency in the sampling and analytical methods used.Few studies report the concentration of SARS-CoV-2 in air or as surface loading of virus RNA, and very few studies have reported culture of the virus.The best estimate of typical air concentrations in health care settings is around 0.01 SARS-CoV-2 virus RNA copies/m3How might this impact on policy or clinical practice in the foreseeable future?There should be concerted efforts to standardise the methods used for measuring SARS-CoV-2 and other respiratory viruses in work environments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was carried out within a project on the Evaluation of the Effectiveness of Novel workplace interventions in protecting healthcare workers from virus infection, funded by the Scottish Chief Scientists Office (Grant no: COV/IOM/20/01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper describes a systematic review and there were no ethical issues involved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data extracted from the literature are included in tables in the manuscript.